Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
Primary: The primary objective of the study is to compare the efficacy of intranasal oxytocin
 in reducing the weekly percentage of heavy drinking days over the 12 weeks of treatment among
 subjects with moderate to severe Alcohol Use Disorder (AUD). A "heavy drinking day" is 4 or
 more drinks per drinking day for women and 5 or more drinks per drinking day for men.

 Secondary: Secondary objectives include assessment of other measures of the effects of
 oxytocin compared with placebo on reduction of alcohol use as well as effects on
 psychological assessments, alcohol craving, alcohol-related consequences, cigarette smoking
 and other nicotine use, retention in the study, and safety and tolerability throughout the
 study.
Inclusion Criteria:

 1. Be at least 18 years of age.

 2. Have a current (past 12 months) DSM-5 diagnosis of AUD (4 or more symptoms) assessed
 using the MINI neuropsychiatric interview version 7.0.2 (at least moderate severity,
 ICD-10-CM Code F10.20 alcohol dependence, uncomplicated).

 3. Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent
 document (either just prior to or immediately after signing consent).

 4. Be seeking treatment for problems with alcohol reduction in drinking.

 5. Be able to verbalize an understanding of the consent form, able to provide written
 informed consent, verbalize willingness to complete study procedures, able to
 understand written and oral instructions in English and able to complete the
 questionnaires required by the protocol.

 6. Agree (if the subject is female and of child bearing potential) to use at least one of
 the following methods of birth control, unless she is surgically sterile, partner is
 surgically sterile or she is postmenopausal:

 1. oral contraceptives,

 2. contraceptive sponge,

 3. patch,

 4. double barrier (diaphragm/spermicidal or condom/spermicidal),

 5. intrauterine contraceptive system,

 6. etonogestrel implant,

 7. medroxyprogesterone acetate contraceptive injection,

 8. complete abstinence from sexual intercourse, and/or

 9. hormonal vaginal contraceptive ring.

 7. Be able to take intranasal investigational products and be willing to adhere to the
 investigational product regimen.

 8. Complete all assessments required at screening and baseline.

 9. Have a place to live in the 2 weeks prior to randomization and not be at risk that
 s/he will lose his/her housing by Study Week 14.

 10. Not anticipate any significant problems with transportation arrangements or available
 time to travel to the study site by Study Week 14.

 11. Not have any plans to move within Study Week 14 to a location which would make
 continued participation in the study impractical.

 12. Not have any unresolved legal problems that could jeopardize continuation or
 completion of the study.

 13. Provide contact information of someone, such as a family member, spouse, or
 significant other, who may be able to contact the subject in case of a missed clinic
 appointment.

 14. Be someone who in the opinion of the investigator would be expected to complete the
 study protocol.

 15. Agree to the schedule of visits, verbally acknowledge that s/he will be able to attend
 each scheduled visit, participate in phone visits and that s/he does not have any
 already scheduled events or a job that may substantially interfere with study
 participation.

 16. If taking a medication for depression or anxiety, must have been taking a stable dose
 in the 2-months prior to randomization and plan to continue during the study. This
 includes drugs such as the following:

 -  SSRIs

 -  Dual uptake inhibitors

 -  SNRIs

 -  Tricyclic antidepressants

 -  MAOIs

 -  Bupropion

 17. Not currently taking oxytocin and agree not to take non-study oxytocin for the
 duration of the study.

 Exclusion Criteria:

 Contact study site for exclusion criteria.